Winning the best paper award at PacificVis 2022, a research team has developed a resolution-precision-adaptive representation technique that reduces mesh sizes, thereby reducing the memory and storage footprints of large scientific datasets.
Kevin McLoughlin has always been fascinated by the intersection of computing and biology. His LLNL career encompasses award-winning microbial detection technology, a COVID-19 antiviral drug design pipeline, and work with the ATOM consortium.
Technologies developed through the Next-Generation High Performance Computing Network project are expected to support mission-critical applications for HPC, AI and ML, and high performance data analytics. Applications could include stockpile stewardship, fusion research, advanced manufacturing, climate research and other open science on future ASC HPC systems.
The Exascale Computing Project (ECP) 2022 Community Birds-of-a-Feather Days will take place May 10–12 via Zoom. The event provides an opportunity for the HPC community to engage with ECP teams to discuss our latest development efforts.
Sponsored by the DSI, LLNL’s winter hackathon took place on February 16–17. In addition to traditional hacking, the hackathon included a special datathon competition in anticipation of the Women in Data Science (WiDS) conference on March 7.
LLNL researchers and collaborators have developed a highly detailed, ML–backed multiscale model revealing the importance of lipids to RAS, a family of proteins whose mutations are linked to many cancers.
The Data Science Institute hosted a career panel featuring members of some of LLNL's Employee Resource Groups: Asian Pacific American Council, Amigos Unidos Hispanics in Partnership, Women’s Association, and Abilities Champions.
LLNL will lend its expertise in vaccine research and computing resources to the Human Vaccines Project consortium to aid development of a universal coronavirus vaccine and improve understanding of immune response.
Computational biology is using HPC to rapidly design and develop ways to treat cancer and COVID. LLNL researcher Felice Lightstone discusses ATOM (Accelerated Therapeutic Opportunities in Medicine) in this edition of SC21 TV.